Applechat Applechat
Resultados de la búsqueda
Ver todos los resultados
  • Participar
    Iniciar sesión
    Registrarse
    Buscar
    Night Mode

Buscar

Descubre nuevas personas, crear nuevas conexiones y hacer nuevos amigos

  • Noticias Feed
  • EXPLORE
  • Páginas
  • Grupos
  • Eventos
  • Reels
  • Blogs
  • Ofertas
  • Empleos
  • Entradas
  • Blogs
  • Usuarios
  • Páginas
  • Grupos
  • Eventos
  • Pratiksha Chokhande agregó una foto Health
    2026-06-16 06:51:54 -
    Dextromethorphan Market Assessment and Competitive Analysis Report
    "Dextromethorphan Market  Summary According to the latest report published by Data Bridge Market Research, the Dextromethorphan Market Data Bridge Market Research analyses that the global dextromethorphan market which was USD 487.25 million in 2022, is expected to reach USD 587.31 million by 2030, and is expected to undergo a CAGR of 4.8% during the forecast period of 2023 to...
    0 Commentarios 0 Acciones 544 Views 0 Vista previa
    Please log in to like, share and comment!
  • Pratiksha Chokhande agregó una foto Health
    2026-07-30 10:06:49 -
    Dextromethorphan Market Report: Size, Share, Trends & Forecast to 2033
    "Dextromethorphan Market Summary According to the latest report published by Data Bridge Market Research, the Dextromethorphan Market Data Bridge Market Research analyses that the global dextromethorphan market which was USD 487.25 million in 2022, is expected to reach USD 587.31 million by 2030, and is expected to undergo a CAGR of 4.8% during the forecast period of 2023 to 2030. An...
    0 Commentarios 0 Acciones 120 Views 0 Vista previa
    Please log in to like, share and comment!
  • Surbhi Verma agregó una foto Health
    2026-07-24 11:05:21 -
    Pseudobulbar Treatment Market: How Is Dextromethorphan-Quinidine Fixed-Dose Therapy Becoming the Fastest-Growing Pharmacological Standard?
    Dextromethorphan-quinidine fixed-dose combination (Nuedexta, Avanir/Otsuka) — the first FDA-approved therapy specifically indicated for pseudobulbar affect (PBA) in amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) patients, modulating glutamatergic and sigma-1 receptor signaling while inhibiting CYP2D6 metabolism — creates the most commercially dynamic market segment,...
    0 Commentarios 0 Acciones 152 Views 0 Vista previa
    Please log in to like, share and comment!
© 2026 Applechat Spanish
English Arabic French Spanish Portuguese Deutsch Turkish Dutch Italiano Russian Romaian Portuguese (Brazil) Greek
About Términos Privacidad Contact Us Directorio